People · Operator
Named in public records as an officer, director or promoter · active 2011–2024 · Biotechnology, Energy Conservation, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Immunis, Inc. | — | Biotechnology | Series B | $20.4M | $147.9M | 2024 |
| GMZ Energy, Inc. | — | Energy Conservation | Series A | $12.9M | $31.8M | 2011 |
| Cyrano Therapeutics, Inc. | — | Pharma | Series A | $4.1M | $108.4M | 2020 |
Takahide Koda at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Takahide Koda on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Gerry Brunk | 1 | 5 |
| Ilya Golubovich | 1 | 4 |
| Aaron Bent | 1 | 3 |
| Richard Geoffrion | 1 | 3 |
| Hans Keirstead | 1 | 3 |
| Daniel Kraft | 1 | 3 |
| David Waserstein | 1 | 2 |
| CHERYL DIUGUID | 1 | 1 |
| Gang Chen | 1 | 1 |
| Michael Clary | 1 | 1 |
| Gabriel Nistor | 1 | 1 |
| Robert Henkin | 1 | 1 |
| MIKE CLARY | 1 | 1 |
| Issam Dairanieh | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.